Research information only, not medical advice. GLP-1 receptor agonist, FDA-approved as Ozempic (subcutaneous, Dec 2017) for type 2 diabetes and as Wegovy (2.4 mg subcutaneous, Jun 2021) for chronic weight management; Wegovy was additionally approved Mar 2024 to reduce major cardiovascular events in adults with established cardiovascular disease plus overweight/obesity.
Semaglutide at a glance
Semaglutide is a long-acting GLP-1 analogue that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and reduces appetite. Its evidence base consists of large phase 3 randomized controlled trials. In STEP 1 (1,961 adults with overweight/obesity, no diabetes), once-weekly semaglutide 2.4 mg produced a mean body-weight change of -14.9% vs -2.4% with placebo at week 68 (Wilding et al., NEJM 2021, PMID 33567185). In SUSTAIN-6 (3,297 patients with type 2 diabetes at high cardiovascular risk), semaglutide significantly lowered the rate of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke versus placebo over 104 weeks (Marso et al., NEJM 2016, PMID 27633186). The most common adverse effects are gastrointestinal (nausea, vomiting, diarrhea, constipation). Labeling carries a boxed warning for risk of thyroid C-cell tumors based on rodent data and is contraindicated in personal or family history of medullary thyroid carcinoma or MEN 2, with additional warnings for pancreatitis, gallbladder disease, diabetic retinopathy complications, acute kidney injury, and hypoglycemia when combined with insulin or sulfonylureas.
See how we grade evidence for the methodology behind this page.
Evidence profile
771 studies- Human RCT 40 · 5%
- Human trial 121 · 16%
- Review 264 · 34%
- Animal 65 · 8%
- In-vitro 46 · 6%
- Unknown 235 · 30%
The longer the green, the stronger the human evidence. For most research peptides the bar is dominated by animal and in-vitro work, which is a signal to read every claim carefully.
Regulatory status
Clinical trials
-
A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide
-
A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects
-
Effect of Renal Impairment on the Pharmacokinetics of NN9535
-
Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects
-
Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects
-
Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes
- NCT01511393 ENROLLING_BY_INVITATION
An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
-
Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects
-
Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects
-
Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes
-
Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
-
A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes
-
Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes
-
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes
-
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function
-
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
-
Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects
-
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes
-
Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects
-
Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes
-
A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects
-
A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects
-
Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects
-
Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
-
A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes
-
Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide
-
Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects
-
Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects
-
A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes
-
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes
-
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
-
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
-
Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.
-
A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes
-
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment
-
A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females
-
Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.
-
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
-
Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus
-
Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.
-
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only
-
A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects.
-
A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects
-
Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes
-
Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes
-
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin
-
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
-
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus
-
Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes
-
Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes
-
A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects
-
Once Weekly GLP-1 in Persons With Spinal Cord Injury
-
A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver
-
Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging
-
STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
-
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
-
Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
-
A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese
- NCT03631186 COMPLETED
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)
-
Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men
- NCT03648281 COMPLETED
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN)
-
GLP1R in Parkinson's Disease
-
A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes
-
Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
-
A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese
-
A Study Comparing the Dulaglutide Pen and the Semaglutide Pen
-
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
-
STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity
-
A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity
-
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
-
Triple Therapy in T1DM
-
Treating PCOS With Semaglutide vs Active Lifestyle Intervention
- NCT03929679 COMPLETED
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)
-
A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)
-
Semaglutide Treatment On Coronary Progression
-
Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)
-
A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
-
A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity
-
A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity
-
A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese
-
A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes
-
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
- NCT04083820 COMPLETED
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)
- NCT04094415 COMPLETED
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice
-
Impact of Semaglutide on CD34+ EPC and Fat Derived MSC
-
A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity
-
A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens
-
Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV
- NCT04175665 COMPLETED
Real-world Health Outcomes in Canadian Patients Using Semaglutide
-
A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity
-
Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc
- NCT04200625 COMPLETED
Semaglutide vs Dulaglutide on Epicardial Adipose Tissue
-
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
-
Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.
-
SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
-
Exercise and GLP-1 RA on Insulin Secretion
-
16-week Flexible vs. 8-week Semaglutide Titration
-
Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder
-
A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times
-
Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy People
- NCT04537637 COMPLETED
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical Practice
-
A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes
- NCT04572165 COMPLETED
Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data
- NCT04601753 COMPLETED
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical Practice
-
Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19
-
Treatment of GLP-1 for Diabetic Bariatric Patients
-
Combined Active Treatment in Type 2 Diabetes With NASH
-
The Effect of Semaglutide on Bone Turnover in Patients With Increased Risk of Bone Fracture
-
Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes
-
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
-
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
-
GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight
-
Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity
-
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
-
Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes
- NCT04862923 COMPLETED
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in the United Kingdom, as Part of Local Clinical Practice
-
The Effect of Semaglutide on Pituitary Function
-
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
-
Lifestyle Counseling and Medication for Adolescent Weight Management
- NCT04878393 COMPLETED
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Japan, as Part of Local Clinical Practice
-
A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men
-
Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients
-
SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes
-
Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?
-
Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
-
Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care
-
A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity
-
Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
-
Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)
-
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
-
Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity
-
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
-
Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)
-
Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)
-
Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes
-
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
-
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
-
Latino Semaglutide Study
-
Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes
-
A Research Study Looking at New Protein-based Tablets in Healthy Male Participants
-
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity
- NCT05136287 COMPLETED
SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.
-
Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients
-
A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause
- NCT05161429 UNKNOWN
BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
-
Sit Less, Interact and Move More (SLIMM) 2 Study
-
Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes
-
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
-
Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care
-
A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People
- NCT05230589 COMPLETED
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Saudi Arabia, as Part of Local Clinical Practice
- NCT05230615 COMPLETED
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice
-
A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide
-
A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity
-
Semaglutide Use in Elderly Obese Patients
-
Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes
- NCT05316662 COMPLETED
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice
-
Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity
-
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
-
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
-
A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet
-
A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together
-
A Study of Cardiovascular Events iN Diabetes Plus
-
Efficacy of Oral Semaglutide in Overweight or Obesity
- NCT05443191 COMPLETED
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice
- NCT05443334 COMPLETED
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice
-
Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity
- NCT05468632 COMPLETED
A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE)
- NCT05473286 WITHDRAWN
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
-
A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes
-
A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight
-
A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men
-
Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes
- NCT05503927 ENROLLING_BY_INVITATION
A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy
-
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
-
Semaglutide for Alcohol Use Disorder
-
Effects of Semaglutide on Nicotine Intake
-
Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes
-
ADJUnct Semaglutide Treatment in Type 1 Diabetes
-
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range
-
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
-
Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes
-
Young Adults With Early-onset Obesity Treated With Semaglutide
- NCT05577728 COMPLETED
Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data
-
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
-
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity
-
Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes
-
Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets
-
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
-
Comparison of Body Weight Change Through Different Smeglutide Administration Methods
- NCT05622045 ACTIVE_NOT_RECRUITING
Does Personality Predict Patient Adherence, Health Behaviors, and Weight Loss Outcomes During the Latino Crossover Semaglutide Study (LCSS)? (Story-LCSS Project)
-
Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke
-
A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight
-
Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant
-
A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose
-
Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome
-
Semaglutide Treatment for Hyperglycaemia After Renal Transplantation
- NCT05714683 NOT_YET_RECRUITING
Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
-
Feasibility of Semaglutide in Advanced Lung Disease
-
A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906
-
Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue
- NCT05755360 COMPLETED
DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy
-
A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations
- NCT05768945 COMPLETED
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors
-
Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus
-
Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults
-
Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity
-
Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes
-
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
-
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
-
Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia
-
Novel Therapeutics and Endothelial Dysfunction in T1DM Patients
-
Semaglutide and Vascular Regeneration
-
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease
-
Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)
-
Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study
-
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies
-
Preoperative Weight Loss for Open Abdominal Wall Reconstruction
-
The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
-
Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes
-
Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years
-
A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy Participants
-
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
-
Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM
-
Semaglutide Therapy for Alcohol Reduction (STAR)
-
The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure
-
A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range
-
DIALYSIS-TIR Study
-
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
-
Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus
-
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
-
Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes
-
Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes
-
A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III
- NCT06120556 COMPLETED
Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes
-
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
-
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
- NCT06154486 COMPLETED
Evaluation of Gastric Content of Volunteers Fasting and Using Semaglutide: an Observational and Cross-sectional Study
-
Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus
-
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
-
DUTCH Weight Control in Atrial Fibrillation Study
-
Effectiveness and Safety of Semaglutide Combined With Dietary Fiber (Soloways) in Adults With Overweight or Obesity
-
Preventing Weight Regain Post-Semaglutide Treatment With Active Fiber Supplement (Soloways)
-
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
- NCT06234111 ACTIVE_NOT_RECRUITING
Semaglutide and Physical Activity for Obesity and Multimorbidity
-
The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients
-
A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus
-
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
-
A Study of How CagriSema Works on Appetite in People With Excess Body Weight
- NCT06269120 RECRUITING
SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary
- NCT06283667 ACTIVE_NOT_RECRUITING
Special Use - Results Surveillance on Long-term Use With Wegovy®
-
Gastric Ultrasound To Assess Gastric Contents In Patients On Semaglutide Therapy
-
GENETIC VARIABILITY TO GLP1 TREATMENT
-
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
-
The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced Diabetes
-
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
-
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
-
GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab
-
Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes
- NCT06351748 COMPLETED
Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)
-
Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment
-
Semaglutide and Cognition in Healthy Volunteers
-
The Medically Reproducing Bariatric Surgery (MRB) II Study
-
Fibrosis Lessens After Metabolic Surgery
- NCT06380426 RECRUITING
A Multicenter Pharmacoepidemiological Cohort on Real Life Use of Semaglutide in Adolescents or Adults With Monogenic Obesity
-
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
-
The Effect of Weekly Semaglutide Treatment on Energy Expenditure
-
Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2
-
Study That Tests AD109 in Patients Taking GLP-1 Drugs
-
Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes
-
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
-
Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome
-
Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment
- NCT06420739 ACTIVE_NOT_RECRUITING
The Semaglutide Study
-
A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects
-
Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure
-
Monitoring Patients With Severe Obesity Treated With Wegovy® Using Connected Device: Real-world Data
-
Semaglutide in Auto-HSCT
-
The Effects of Semaglutide on Body Composition and Performance in Military Personnel
-
Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness
-
The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity
-
Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM
-
Open Randomized Study of Comparative Pharmacokinetics and Biosimilarity of GP40221 (GEROPHARM LLC, Russia) and Ozempic®.
-
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
- NCT06500143 COMPLETED
Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery
- NCT06507475 COMPLETED
Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes
-
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
-
Mechanisms of Semaglutide Therapy in Heart Failure Patients
-
GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease
-
GLP-1R Agonist Treatment for Opioid Use Disorder
-
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
- NCT06581120 ENROLLING_BY_INVITATION
GLP_1 RA Ultrasound Study
-
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
-
Semaglutide in Treatment of Obesity
-
A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)
-
Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function
-
Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes
-
A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®
-
Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.
-
Semaglutide for Helping Opioid Recovery
-
Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants
-
A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
- NCT06659679 COMPLETED
Emulating the PIONEER6 Diabetes Trial Using Healthcare Claims
- NCT06659718 COMPLETED
Emulation of the SOUL Diabetes Trial in Healthcare Claims
- NCT06659744 COMPLETED
Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims
-
A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)
-
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
-
Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Diabetes
-
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity
-
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
-
MAINTAIN (Mucosal AblatIoN Therapy After INcretins)
-
A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
-
A Study of a Weight Loss Intervention in People With Endometrial Cancer
-
Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients
- NCT06761703 COMPLETED
A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss
-
Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes
-
Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity
-
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus
- NCT06790160 RECRUITING
Study of Patients Being Treated With Anti-obesity Medication
-
A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma
-
Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions
-
Bariatric Surgery vs. Semaglutide vs. Tirzepatide
-
A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use
-
Optimization of Obesity for Total Knee Replacement With Glucagon-like Peptide-1 Receptor Agonist
-
A Study of a Novel Precision Medicine Approach For Obesity
- NCT06820047 COMPLETED
Sleeve Gastrectomy vs. Lifestyle & Medications: Impact on BMI Trajectory and Target Attainment in a Matched Cohort Study
- NCT06821919 RECRUITING
Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps)
-
Effect of Aqueous Extracts of Cissus Quadrangularis and Dichrostachys Glomerata on GLP-1 Concentration and DPP-4 Activity in Overweight and Obese Adults
-
The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity
-
The Evira Study: Additional Support During Obesity Treatment
-
JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity
- NCT06856291 RECRUITING
Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance
- NCT06856928 NOT_YET_RECRUITING
Impact of Antiobesity Medications on Appetite and Appetite-related Hormones and Metabolites.
- NCT06874751 COMPLETED
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World
-
LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy
-
Semaglutide in Women With Polycystic Ovary Syndrome and Obesity
-
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
-
Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy
-
Semaglutide Treatment in Type 1 Diabetes
-
Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus
- NCT06914102 COMPLETED
Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data
- NCT06914141 COMPLETED
Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction
-
Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study
-
A Study of BGM0504 in Chinese Patients With Type 2 Diabetes
-
GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward
- NCT06980623 ACTIVE_NOT_RECRUITING
Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction
-
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
- NCT06983171 ACTIVE_NOT_RECRUITING
Semaglutide Effectiveness in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease in the Real World Practice
-
Impact of Semaglutide on Tobacco Use and Related Health Behaviors
-
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
-
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
-
Metabolic Surgery for Atrial Fibrillation Elimination
-
Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial
-
Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients
-
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
- NCT07041983 ENROLLING_BY_INVITATION
24-h Energy Expenditure and Anti-obesity Medication
-
Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes
- NCT07055607 ENROLLING_BY_INVITATION
A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice
-
Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women
-
Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease
-
A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
-
A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)
-
Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement
-
Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity
-
Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures
-
Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation
-
Tolerance of a High Protein Nutrition Shake in Individuals on GLP-1
-
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
- NCT07115069 ACTIVE_NOT_RECRUITING
Comparison of Body Composition Changes With Weight Loss Interventions
-
Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity
-
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects
- NCT07154238 ENROLLING_BY_INVITATION
Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.
- NCT07156331 NOT_YET_RECRUITING
Research on Effects of Drugs on Body Composition and Function With Imaging in Diabetes
- NCT07169136 RECRUITING
Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)
-
A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM
-
Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction
-
Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health
-
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
- NCT07188545 ACTIVE_NOT_RECRUITING
Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
- NCT07190144 COMPLETED
Coronary Flow Reserve Changes After Semaglutide Treatment
-
Oral Semaglutide in Patients With Alzheimer's Disease
-
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
- NCT07216651 COMPLETED
WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults
-
Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)
-
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
-
Repurposing Semaglutide for the Treatment of Cocaine Use Disorder
-
A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease
-
Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.
-
Combination Therapy for Alcohol Use Disorder
-
GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
-
Effect of Itopride on Semaglutide Gastroparesis
-
A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes
-
The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes
- NCT07276763 NOT_YET_RECRUITING
Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention
- NCT07280221 ENROLLING_BY_INVITATION
WEgovy Real World Assessment of Weight Loss in Korea
-
Effect of a Low-carbohydrate Diet on Weight Loss in People Using the Injectable GLP-1 Agonist Semaglutide for Weight Loss
-
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
-
Semaglutide (Wegovy) Treatment for Trichotillomania
-
A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity
-
Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity
-
Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)
-
Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.
-
Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity
- NCT07323134 NOT_YET_RECRUITING
The Effect of Semaglutide on the Intestinal Flora in Obesity
-
Incretin Microdosing for Cardiometabolic Health in People With HIV
-
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight
-
IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion
-
Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus
- NCT07382388 NOT_YET_RECRUITING
A Real-World Study on the Impact of Weight Loss on Treatment Efficacy in Overweight/Obese Patients With Plaque Psoriasis
-
Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation
-
Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.
-
Reversal to Normoglycemia by Treating Prediabetes
- NCT07417618 COMPLETED
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)
- NCT07424430 NOT_YET_RECRUITING
Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes
-
Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes
-
Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant
-
GLP-1 RA for Stage 1 Type 1 Diabetes
- NCT07444073 NOT_YET_RECRUITING
Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock
-
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
- NCT07456774 ENROLLING_BY_INVITATION
A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China
- NCT07457424 ACTIVE_NOT_RECRUITING
Direct Measurement of Microstructure of Ingestive Behaviour After Initiation of GLP-1 Receptor Agonist Treatment at Maximum Dose (DIGRAT)
-
SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer
-
A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults
-
MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal Disease
-
DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies
-
Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes
-
Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes
-
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
-
MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial
-
Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study
-
Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults
-
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
-
A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers
-
Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1
-
Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes
-
Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus
-
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
-
Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM
-
Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients
-
Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)
- NCT07588984 NOT_YET_RECRUITING
GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study
-
Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs
-
Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss
-
Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves
-
GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial
-
GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis
- NCT07619495 COMPLETED
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk
- NCT07619508 COMPLETED
Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes.
- NCT07621419 RECRUITING
Study of Adult Patients Residing in Argentina Diagnosed With Type 2 Diabetes Treated With a New Formulation of Semaglutide, Both Oral and Subcutaneous, in a Real-world Setting at 3 Months, 6 Months, and 1 Year of Follow-up, Quantifying the Reduction in Glycated Hemoglobin
-
Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study)
-
BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity
- NCT07627074 RECRUITING
Weight Loss in Adults Using Semaglutide (Real-world Study)
-
GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer
-
BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes
-
A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
- NCT07640139 ENROLLING_BY_INVITATION
Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes
-
Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy
-
Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease
- NCT07653412 RECRUITING
Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.
-
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
-
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
- NCT07668765 NOT_YET_RECRUITING
GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity
-
Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
- NCT07677865 COMPLETED
GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation
- NCT07695454 NOT_YET_RECRUITING
Imaging in Semaglutide Study
- NCT07701005 COMPLETED
Non-Invasive Hepatic and Metabolic Index Changes After Incretin Therapy in Overweight/Obesity
- NCT07702461 RECRUITING
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
-
Can Two Dietary Interventions Maintain Weight Loss for 12 Months After GLP-1 Therapy in Adults With Overweight/Obesity?
- NCT07720466 NOT_YET_RECRUITING
Salivary Function and Dental Changes During GLP-1 Therapy
-
A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
-
Digital Dietary Intervention for Patients Receiving GLP-1 Receptor Agonist Therapy
-
Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy
-
Effects of Semaglutide on Brain Dopamine Responses to Food Cues in Adults With Obesity and Food Addiction Tendencies
-
Myocardial Metabolic Flux in Pulmonary Arterial Hypertension
-
Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults
- NCT07760532 NOT_YET_RECRUITING
Comparing Facial Aging Between Identical Twins With 3D Imaging
-
HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide
-
A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity
-
Semaglutide in Youth With Autism Spectrum Disorder
-
Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome
-
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
-
OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management Programme
- NCT07781371 NOT_YET_RECRUITING
A Retrospective Real-World Cohort Study
-
A Randomized Controlled Study of Dose-tapering Regimen of Semaglutide for Weight-Loss Maintenance in Adults With Overweight or Obesity
Indexed research
Sorted by evidence level, strongest first.
- Human RCT 2026Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes
This study compares weekly and biweekly bofanglutide versus semaglutide in Chinese patients with type 2 diabetes.
- Human RCT 2026Available datapackage for study 'Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes. A 30-week Randomised, Double-blind, Double-dummy, Active-controlled, Parallel-group, Multi-centre and Multi-national Trial'
This dataset provides data from a 30-week randomized double-blind trial comparing once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in subjects with type 2 diabetes.
- Human RCT 2026Semaglutide reduces drinking in adults with alcohol use disorder and obesity
A 26-week trial found that weekly semaglutide reduced heavy drinking more than placebo in adults with alcohol use disorder and obesity.
- Human RCT 2026Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
- Human RCT 2026Effect of Semaglutide on Measured vs Estimated Glomerular Filtration Rate
This study examined the effect of semaglutide on measured and estimated glomerular filtration rates in individuals with type 2 diabetes and albuminuria.
- Human RCT 2026Semaglutide Injection Once-Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active-Controlled Study
This phase III randomized non-inferiority trial in adults with obesity or overweight found that a synthetic semaglutide injection was non-inferior to Wegovy for weight management over 24 weeks.
- Human RCT 2026Protocol for Novel Perioperative Optimization of Obese Osteoarthritic Patients pending Total Knee Replacement with glucagon-like peptide-1 receptor agonist (NPO-OOPS-TKR)
This pilot randomized trial evaluates the feasibility, tolerability, and acceptability of using semaglutide (a GLP-1 receptor agonist) for perioperative optimization in older Asian adults with obesity undergoing total knee arthroplasty.
- Human RCT 2026Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes
- Human RCT 2026Semaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III, Active-Controlled Study
- Human RCT 2026Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial
This subpopulation analysis of the SURMOUNT-5 trial found that tirzepatide led to greater reductions in body weight, BMI, and waist circumference compared to semaglutide in individuals meeting Japan's obesity disease criteria.
+ 761 more studies indexed for Semaglutide.
Frequently asked questions
- Is Semaglutide approved for human use?
- GLP-1 receptor agonist, FDA-approved as Ozempic (subcutaneous, Dec 2017) for type 2 diabetes and as Wegovy (2.4 mg subcutaneous, Jun 2021) for chronic weight management; Wegovy was additionally approved Mar 2024 to reduce major cardiovascular events in adults with established cardiovascular disease plus overweight/obesity.
- What does the research on Semaglutide show?
- Semaglutide is a long-acting GLP-1 analogue that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and reduces appetite. Its evidence base consists of large phase 3 randomized controlled trials. In STEP 1 (1,961 adults with overweight/obesity, no diabetes), once-weekly semaglutide 2.4 mg produced a mean body-weight change of -14.9% vs -2.4% with placebo at week 68 (Wilding et al., NEJM 2021, PMID 33567185). In SUSTAIN-6 (3,297 patients with type 2 diabetes at high cardiovascular risk), semaglutide significantly lowered the rate of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke versus placebo over 104 weeks (Marso et al., NEJM 2016, PMID 27633186). The most common adverse effects are gastrointestinal (nausea, vomiting, diarrhea, constipation). Labeling carries a boxed warning for risk of thyroid C-cell tumors based on rodent data and is contraindicated in personal or family history of medullary thyroid carcinoma or MEN 2, with additional warnings for pancreatitis, gallbladder disease, diabetic retinopathy complications, acute kidney injury, and hypoglycemia when combined with insulin or sulfonylureas.